

News Release

April 27, 2023

Taiho Pharmaceutical Co., Ltd.

Taiho Oncology Europe GmbH

CHMP ISSUES POSITIVE OPINION FOR FUTIBATINIB FOR THE TREATMENT OF ADULTS WITH CHOLANGIOCARCINOMA

Taiho Pharmaceutical Co., Ltd. and its European subsidiary Taiho Oncology Europe GmbH announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization (CMA) of futibatinib for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

The CHMP's opinion to recommend the use of futibatinib is now being reviewed by the full EMA. Final marketing authorizations for medical products in the European Union (EU) rests with the European Commission.

Each year, approximately 6,000-8,000 individuals in Europe are diagnosed with CCA,¹ a rare cancer of the bile ducts of the liver, and approximately 0.3-6 people per 100,000 individuals live with CCA worldwide.²

"CCA is an aggressive cancer, and the current five-year survival rate is very poor, which underscores the need for new treatment options" said Peter Foertig, MD, Vice President, Medical Affairs, Taiho Oncology Europe. "We look forward to working with the European Medicines Agency as it reviews the application for

marketing authorization.”

The positive CHMP opinion on futibatinib is based on data from the pivotal Phase 2 FOENIX-CCA2[※] trial in 103 patients with locally advanced or metastatic unresectable intrahepatic (inside the liver) CCA, harboring *FGFR2* fusions or rearrangements who had received one or more prior lines of systemic therapy. Patients in the trial received futibatinib 20mg once daily until disease progression or unacceptable toxicity. The trial’s primary endpoint was an objective response rate (ORR).

※ FOENIX-CCA2 : PHASE 1/2 STUDY OF TAS-120 IN PATIENTS WITH ADVANCED SOLID TUMORS Harboring FGF/FGFR Aberrations; FGFR Oral Selective Novel Inhibitor X[across] tumors

Results from the trial were published in the January 19, 2023, issue of *The New England Journal of Medicine*.

“As someone who treats patients with CCA, I am encouraged by these data and the positive news from CHMP,” said Professor Arndt Vogel, MD, Senior Consultant, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany. “The study findings underscore the importance of molecular profiling for patients with CCA and other diseases whenever possible to potentially help improve outcomes. Indeed, the ESMO Clinical Practice Guidelines recommend FGFR inhibitors for the treatment of patients with CCA and FGFR2 fusions who have progressed after one or more prior lines of systemic therapy.”

Takeshi Sagara Ph.D., Managing Director, Clinical Development and Medical Affairs, Discovery and Preclinical Research at Taiho Pharmaceutical, added “The global Taiho group will continue its efforts to bring futibatinib as a new treatment option to patients with CCA around the world, and the positive CHMP opinion represents a big step for Taiho in Europe to deliver innovative drugs to help patients with CCA in their journey”.

About Futibatinib

Futibatinib (TAS-120) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients

with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarcinoma, who were previously treated with chemotherapy or other therapies. Futibatinib covalently binds to the ATP binding pocket of FGFR1-4 resulting in the inhibition of FGFR-mediated signal transduction pathways, reduced tumor cell proliferation in tumors with FGFR1-4 genetic aberrations.

In Japan, a new drug application for futibatinib has been submitted to the Japanese Ministry of Health, Labour and Welfare, as a treatment for previously treated locally advanced or metastatic biliary tract cancer harboring *FGFR2* gene rearrangements, including gene fusions, on July 2022. Furthermore, in September 2022, the U.S. Food and Drug Administration (FDA) approved futibatinib for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma (iCCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.

About Taiho Oncology Europe

The mission of Taiho Oncology Europe is to improve the lives of patients with cancer, their families, and their caregivers. The company specializes in orally administered anti-cancer agents and has a growing pipeline of selectively targeted anti-cancer agents. Taiho Oncology Europe GmbH (Zug, Switzerland) is the European subsidiary of Taiho Pharmaceutical Co., Ltd. (Tokyo, Japan).

For more information, visit www.taihooncology.eu

About Taiho Pharmaceutical Co., Ltd.

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd. (<https://www.otsuka.com/en/>), is an R&D-driven specialty pharma focusing on the fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology, in particular, Taiho Pharmaceutical is known as a leading company in Japan for developing innovative medicines for the treatment of cancer, a reputation that is rapidly expanding through their extensive global R&D efforts. In areas other than oncology, as well, the company creates and markets quality products that effectively treat medical conditions and can help improve people’s quality of life. Always putting customers first, Taiho Pharmaceutical also aims to offer consumer healthcare products that support people’s efforts to lead fulfilling and rewarding

lives. For more information about Taiho Pharmaceutical, please visit <https://www.taiho.co.jp/en/>

1: Kirstein MM, Vogel A. Epidemiology and Risk Factors of Cholangiocarcinoma. *Visc Med.* 2016 Dec;32(6):395-400. Erratum in: *Visc Med.* 2017 Jun;33(3):226.

2: Banales, J M, Marin, J JG, Lamarca, A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. *Nature Reviews Gastroenterology & Hepatology.* 17: 557-588 (2020).